INVAC-1

DB16196Investigational

INVAC-1 is under investigation in clinical trial NCT03265717 (DNA Plasmid Encoding a Modified Human Telomerase Reverse Transcriptase (Htert), Invac-1 in Chronic Lymphocytic Leukemia).

Mechanism: Pharmacologically active on Telomerase reverse transcriptase
Curator reviewed
Also known as: Human telomerase reverse transcriptase (htert) dna vaccine invac-1 · Invac-1, a double stranded dna plasmid vaccine construct encoding ubiquitin-human telomerase reverse transcriptase (htert) fusion protein
Code names: INVAC-1

Resolves to

Compound

UNIIS8GQZ8LF0DCAS1708137-44-3

Targets

O14746TERT

What you can answer from here — as of July 08, 2026

1Protein targetEach mapped to UniProt, with action and pharmacological action

Listed above

3Clinical trialsPhase, status and sponsor resolved per trial

3+ReferencesStructured and connected to the statements they support

Which drugs share a target with INVAC-1, and which of those have an active Phase 3 trial?

Answer this in Biopharma OS Sign in to your account

Create a free account or log in to explore the full data card.

Create Account